{"id":"https://openalex.org/W2946972740","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.3004","title":"First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.","display_name":"First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2946972740","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.3004","mag":"2946972740"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.3004","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.3004","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.3004","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060580923","display_name":"George D. Demetri","orcid":"https://orcid.org/0000-0002-0045-4809","observed_orcids":["https://orcid.org/0000-0002-0045-4809"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George D. Demetri","raw_affiliation_strings":["Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason J. Luke","raw_affiliation_strings":["The University of Chicago Medicine, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medicine, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086593040","display_name":"Antoine Hollebecque","orcid":"https://orcid.org/0000-0003-2869-7551","observed_orcids":["https://orcid.org/0000-0003-2869-7551"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Antoine Hollebecque","raw_affiliation_strings":["Gustave Roussy, Villejuif, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy, Villejuif, France;","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090977453","display_name":"John D. Powderly","orcid":"https://orcid.org/0000-0002-7608-0380","observed_orcids":["https://orcid.org/0000-0002-7608-0380"]},"institutions":[{"id":"https://openalex.org/I4210093858","display_name":"Carolina BioOncology Institute","ror":"https://ror.org/00htvrc11","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210093858"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John D. Powderly","raw_affiliation_strings":["Carolina BioOncology Institute, Huntersville, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Carolina BioOncology Institute, Huntersville, NC;","institution_ids":["https://openalex.org/I4210093858"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044613951","display_name":"Alexander I. Spira","orcid":"https://orcid.org/0000-0003-1303-0447","observed_orcids":["https://orcid.org/0000-0003-1303-0447"]},"institutions":[{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander I. Spira","raw_affiliation_strings":["Virginia Cancer Specialists, Fairfax, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Cancer Specialists, Fairfax, VA;","institution_ids":["https://openalex.org/I4210122908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043675371","display_name":"Vivek Subbiah","orcid":"https://orcid.org/0000-0002-6064-6837","observed_orcids":["https://orcid.org/0000-0002-6064-6837"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivek Subbiah","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061250882","display_name":"Dominic W. Lai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dominic W. Lai","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110415017","display_name":"Huibin Yue","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Huibin Yue","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039202929","display_name":"Sreeneeranj Kasichayanula","orcid":"https://orcid.org/0000-0002-2671-8550","observed_orcids":["https://orcid.org/0000-0002-2671-8550"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sreeneeranj Kasichayanula","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000724954","display_name":"Scott H. Gulbranson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Gulbranson","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110755706","display_name":"James W. Purcell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Purcell","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041977533","display_name":"Melinda C. Myzak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melinda Myzak","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052500665","display_name":"Randy R. Robinson","orcid":"https://orcid.org/0000-0002-9503-1111","observed_orcids":["https://orcid.org/0000-0002-9503-1111"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Randy Robinson","raw_affiliation_strings":["Oncology Early Development, AbbVie Inc., Redwood City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Early Development, AbbVie Inc., Redwood City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045901657","display_name":"Victor Manuel Villalobos","orcid":"https://orcid.org/0000-0002-8722-284X","observed_orcids":["https://orcid.org/0000-0002-8722-284X"]},"institutions":[{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victor Manuel Villalobos","raw_affiliation_strings":["University of Colorado, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado, Denver, CO;","institution_ids":["https://openalex.org/I921990950"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony W. Tolcher","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, San Antonio, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, San Antonio, TX;","institution_ids":["https://openalex.org/I4210119066"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"3004","last_page":"3004"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.4336000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.4336000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.38449999690055847,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.01850000023841858,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9819999933242798},{"id":"https://openalex.org/keywords/lrrc15","display_name":"LRRC15","score":0.9860000014305115},{"id":"https://openalex.org/keywords/sarcoma","display_name":"sarcoma","score":0.949999988079071},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9020000100135803},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.9629999995231628},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7950000166893005},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6110000014305115},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6399999856948853},{"id":"https://openalex.org/keywords/cancer-associated-fibroblasts","display_name":"cancer-associated fibroblasts","score":0.7139999866485596},{"id":"https://openalex.org/keywords/first-in-human-safety","display_name":"first-in-human safety","score":0.5609999895095825},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.39399999380111694},{"id":"https://openalex.org/keywords/blurred-vision","display_name":"blurred vision","score":0.6050000190734863},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.6759999990463257},{"id":"https://openalex.org/keywords/hypertriglyceridemia","display_name":"hypertriglyceridemia","score":0.7540000081062317},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.3319999873638153},{"id":"https://openalex.org/keywords/dose-expansion","display_name":"dose expansion","score":0.33000001311302185}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8923681974411011},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6544477939605713},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6060101389884949},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5693936944007874},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.47838154435157776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4758988320827484},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4391276240348816},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.42675989866256714},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3766540288925171},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.329267680644989}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.3004","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.3004","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.3004","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3143023056","https://openalex.org/W2885215235","https://openalex.org/W2560634573","https://openalex.org/W4409689006","https://openalex.org/W3033371454","https://openalex.org/W4399737565","https://openalex.org/W7148748552","https://openalex.org/W2898393111","https://openalex.org/W4405041086","https://openalex.org/W2979486111"],"abstract_inverted_index":{"3004":[0],"Background:":[1],"ABBV-085":[2,43,66,84,339],"is":[3],"an":[4],"ADC":[5],"(conjugated":[6],"to":[7,93],"monomethyl":[8],"auristatin":[9],"E,":[10],"drug:antibody":[11],"ratio":[12],"of":[13,32,39,54,65,113,320],"2:1)":[14],"directed":[15],"against":[16],"leucine-rich":[17],"repeat":[18],"containing":[19],"15":[20],"(LRRC15),":[21],"a":[22,87],"type":[23],"1":[24,107],"transmembrane":[25],"protein":[26],"highly":[27],"expressed":[28],"on":[29,185],"the":[30,63,200,233,244,247,257,260,290],"surface":[31],"sarcomas":[33,284],"and":[34,51,108,123,219,226,282,332],"cancer-associated":[35],"fibroblasts":[36],"in":[37,47,49,67,86,105,120,193,243,347],"stroma":[38],"many":[40],"other":[41,283],"cancers.":[42],"induced":[44],"antitumor":[45],"activity":[46],"both":[48],"vitro":[50],"xenograft":[52],"models":[53],"sarcoma.":[55],"This":[56],"phase":[57,235],"1,":[58],"first-in-human,":[59],"2-part":[60],"study":[61,186],"assessed":[62,104],"safety/tolerability":[64],"patients":[68],"(pts)":[69],"with":[70,343,349],"advanced":[71,80,350],"solid":[72,81],"tumors":[73],"(NCT02565758).":[74],"Methods:":[75],"Eligible":[76],"pts":[77,117,164,178,263,348],"(\u226518":[78],"yr;":[79],"tumors)":[82],"received":[83],"intravenously":[85],"3+3":[88],"dose-escalation":[89],"(DE)":[90],"design;":[91],"0.3-":[92],"4.8-mg/kg":[94],"doses":[95],"every":[96],"2":[97,299,312],"wk":[98,158],"(8":[99],"cohorts).":[100],"Pharmacokinetics":[101],"(PK)":[102],"were":[103,118,191,314],"cycle":[106,109],"3.":[110],"Results:":[111],"As":[112],"Dec":[114],"2018,":[115],"78":[116],"enrolled":[119],"monotherapy":[121],"DE":[122],"dose-expansion":[124],"(EXP)":[125],"cohorts":[126],"(\u22642.7":[127],"mg/kg,":[128,133,138,143],"n":[129,134,139,144],"=":[130,135,140,145,210,216,223,266,269,276,280,286],"21;":[131],"3.6":[132,207,228],"45;":[136],"4.2":[137,213],"6;":[141],"4.8":[142,220],"6);":[146],"median":[147,153,318],"age:":[148],"58":[149],"yr":[150],"(range":[151,159],"21\u201384);":[152],"treatment":[154],"(Tx)":[155],"duration:":[156],"6.2":[157],"0.3\u201354.4).":[160],"Overall,":[161],"77":[162],"(98.7%)":[163],"reported":[165,179,192],"\u22651":[166],"Tx-emergent":[167],"adverse":[168],"events":[169],"(TEAEs).":[170],"Fatigue":[171],"(48.7%)":[172],"was":[173,199,230,253,324,340],"most":[174,201],"common;":[175],"19":[176],"(24.4%)":[177],"grade":[180],"1/2":[181],"blurred":[182],"vision":[183],"(reversible":[184],"discontinuation).":[187],"Grade":[188],"\u22653":[189],"TEAEs":[190],"56":[194],"(71.8%)":[195],"pts;":[196],"anemia":[197],"(14.1%)":[198],"common.":[202],"Dose-limiting":[203],"toxicities":[204],"occurred":[205],"at":[206,256,289],"mg/kg":[208,214,221,229],"(n":[209,215,222],"1;":[211,217],"anemia),":[212],"hypertriglyceridemia),":[218],"2;":[224],"ileus":[225],"nausea);":[227],"chosen":[231],"as":[232],"recommended":[234],"1b":[236],"dose":[237],"(RP1bD).":[238],"PK":[239],"exhibited":[240],"dose-proportional":[241],"increase":[242],"area":[245],"under":[246],"curve":[248],"after":[249],"single-dose":[250],"administration;":[251],"half-life":[252],"2.84":[254],"days":[255],"RP1bD.":[258],"Of":[259],"27":[261],"sarcoma":[262,274],"(DE":[264],"[n":[265,268,275,279,285],"8]/EXP":[267],"19]":[270],"cohorts;":[271],"undifferentiated":[272],"pleomorphic":[273],"10],":[277,281],"osteosarcoma":[278],"7])":[287],"treated":[288],"RP1bD,":[291],"4":[292],"(14.8%)":[293],"had":[294,304,309],"confirmed":[295],"partial":[296],"response":[297,321],"(PR;":[298],"[7.4%]":[300],"unconfirmed),":[301],"8":[302],"(29.6%)":[303],"stable":[305],"disease,":[306],"11":[307],"(40.7%)":[308],"progressive":[310],"disease;":[311],"(7.4%)":[313],"not":[315],"evaluable.":[316],"The":[317],"duration":[319],"(confirmed":[322],"responders)":[323],"7.6":[325],"mo":[326],"(95%":[327],"CI:":[328],"5.6\u20139.2).":[329],"Updated":[330],"safety":[331],"efficacy":[333],"data":[334],"will":[335],"be":[336],"reported.":[337],"Conclusions:":[338],"well":[341],"tolerated":[342],"durable":[344],"PR":[345],"observed":[346],"sarcomas.":[351],"Clinical":[352],"trial":[353],"information:":[354],"NCT02565758.":[355]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2019-06-07T00:00:00"}